Subject: Re:
From: "Irinka Tskhomelidze" <[email-masked]>
To: 26ded . <[email-masked]>
Cc: Mariana Mkurnali;
Date: Mon, 26 Jun 2017 11:39:23 +0400

Dear Dzmitry

Thank you can you please tell us who is responsible for the drug stock so that we can include information about stock in our monthly report.

best regards,

Irina

On Fri, Jun 23, 2017 at 1:31 PM, 26ded . <[email-masked]> wrote:

Dear Irina!

I already wrote to Farhana that employees of the Center of Expertise and Testing in Healthcare are monitoring the side effects in accordance with the legislation of the Republic of Belarus. Svetlana and I are monitoring the observance of the clinical protocol (correct schemes, duration, need for prolongation of treatment, etc.), so, unfortunately, we can not be useful in this capacity. The start of Sovaldi's treatment is in accordance with the plan: next week, the schemes will be initiated in all patients. According to our data, no side effects have been observed at present.

Yours faithfully, Dzmitry Danilau

2017-06-23 12:09 GMT+03:00 Irinka Tskhomelidze <[email-masked]>:

Dear  Danilau and Svetlana ,

Hope this email finds you well.

As per our agreement within HCV elimination project in Belarus you will  report AEs to us.

Could you please also inform us if there is any progress.

Have you already started treatment with Sovaldi and in case if yes how many patients have started treatment.

In case if you are not responsible for this please provide us with POC.

Thank you in advance

​Dear  Danilau and Svetlana we are looking forward to working with you.​

--

Best regards,

Irina Tskhomelidze,

Health Care Department

Ministry of Labour, Health and Social Affairs of Georgia

--

Best regards,

Irina Tskhomelidze,

Health Care Department

Ministry of Labour, Health and Social Affairs of Georgia